Sugi Predict

Sugi Predict / Compounds / SCHEMBL2137609

SCHEMBL2137609

SCHEMBL2137609

CC(C)[C@@H](N)C(=O)OCc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC15A1 P46059 1/20 0.61
▸ ALDH1A1 P00352 4/20 0.56
▸ SLC1A3 P43003 2/20 0.51
▸ SLC1A2 P43004 2/20 0.51
▸ SLC1A1 P43005 2/20 0.51
▸ KMT2A Q03164 2/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ CYP1A2 P05177 1/20 0.51
▸ CYP2D6 P10635 1/20 0.51
▸ CYP2C9 P11712 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ MAPK1 P28482 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ SLC6A2 P23975 1/20 0.50
▸ SLC6A3 Q01959 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ CTSB P07858 1/20 0.48
▸ LTA4H P09960 2/20 0.48
▸ LAP3 P28838 1/20 0.48
▸ LMNA P02545 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL354949 1.00 SLC15A1 (0.61) SLC15A1ALDH1A1SLC1A3SLC1A2SLC1A1
SCHEMBL542444 1.00 SLC15A1 (0.61) SLC15A1ALDH1A1SLC1A3SLC1A2SLC1A1
Hydrochloric Acid SCHEMBL2135391 0.98 SLC15A1 (0.59) SLC15A1ALDH1A1SLC1A3SLC1A2SLC1A1
Hydrochloric Acid SCHEMBL7275901 0.98 SLC15A1 (0.59) SLC15A1ALDH1A1SLC1A3SLC1A2SLC1A1
Hydrochloric Acid SCHEMBL542587 0.98 SLC15A1 (0.59) SLC15A1ALDH1A1SLC1A3SLC1A2SLC1A1
Hydrochloric Acid SCHEMBL2137602 0.98 SLC15A1 (0.59) SLC15A1ALDH1A1SLC1A3SLC1A2SLC1A1
Hydrochloric Acid SCHEMBL7275897 0.98 SLC15A1 (0.59) SLC15A1ALDH1A1SLC1A3SLC1A2SLC1A1
Valine SCHEMBL28244846 0.95 SLC15A1 (0.60) SLC15A1ALDH1A1SLC1A3SLC1A2SLC1A1
Valine SCHEMBL28244847 0.95 SLC15A1 (0.60) SLC15A1ALDH1A1SLC1A3SLC1A2SLC1A1
Lactic Acid SCHEMBL28307486 0.94 SLC15A1 (0.59) SLC15A1ALDH1A1SLC1A3SLC1A2SLC1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122029214-A Phospholipid drug conjugate and preparation method and application thereof 上海弼领生物技术有限公司 2026-05-12 — — CN disclosed
WO-2025067481-A1 PHOSPHOLIPID DRUG CONJUGATE, AND PREPARATION METHOD AND USE THEREFOR 上海弼领生物技术有限公司 2025-04-03 — — WO disclosed
WO-2023075435-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE 주식회사 베르티스 2023-05-04 — — WO disclosed
US-20230056969-A1 METHOD FOR SYNTHESIZING PEPTIDE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-02-23 — — US disclosed
EP-4083051-A1 METHOD FOR SYNTHESIZING PEPTIDE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2022-11-02 — — EP disclosed
CN-114867734-A Method for synthesizing peptide compound 中外制药株式会社 2022-08-05 — — CN disclosed
WO-2022050529-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE ㈜베르티스 2022-03-10 — — WO disclosed
US-10632210-B2 Peptidomimetic compounds and antibody-drug conjugates thereof GENENTECH, INC. (US) 2020-04-28 — — US disclosed
WO-2019238057-A1 APPLICATION OF FSO2N3 IN PREPARATION OF AZIDE 中国科学院上海有机化学研究所 2019-12-19 — — WO disclosed
US-20190083643-A1 PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF GENENTECH, INC. (US) 2019-03-21 — — US disclosed
WO-2000076972-A1 N-CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY MERCK & CO., INC. (US) 2000-12-21 — — WO disclosed
US-6153609-A Arylsulfonylamino hydroxamic acid derivatives PFIZER INC (US) 2000-11-28 — — US disclosed
US-6147074-A Arylsulfonylamino hydroxamic acid derivatives PFIZER INC (US) 2000-11-14 — — US disclosed
WO-2000037436-A1 SULFONAMIDE HYDROXAMATES F. HOFFMANN-LA ROCHE AG (CH) 2000-06-29 — — WO disclosed
US-5994351-A Arylsulfonylamino hydroxamic acid derivatives PFIZER INC. (US) 1999-11-30 — — US disclosed
EP-0922030-A1 ARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES PFIZER INC. (US) 1999-06-16 — — EP disclosed
US-5863949-A Arylsulfonylamino hydroxamic acid derivatives PFIZER INC (US) 1999-01-26 — — US disclosed
WO-1998007697-A1 ARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES PFIZER INC. (US) 1998-02-26 — — WO disclosed
EP-0813520-A1 ARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES PFIZER INC. (US) 1997-12-29 — — EP disclosed
WO-1996027583-A1 ARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES PFIZER INC. (US) 1996-09-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230056969-A1 METHOD FOR SYNTHESIZING PEPTIDE COMPOUND VIP, NGLY1, NPPA SLC15A1 3636/4885ALDH1A1 4601/4885SLC1A3 1584/4885
US-10632210-B2 Peptidomimetic compounds and antibody-drug conjugates thereof DNPEP, LNPEP, BCR SLC15A1 1152/4885ALDH1A1 3237/4885SLC1A3 1513/4885
US-20190083643-A1 PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF DNPEP, LNPEP, BCR SLC15A1 1152/4885ALDH1A1 3237/4885SLC1A3 1513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.